DealPulse Signal Wk 44: Surgery Partners Took $5.7 Billion of the Week’s Upfront, and a Drug Licence Took $70 Million
A surgical network and a radiology group took 98% of the week’s upfront. The only separable drug upfront was $70M.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
The FDA Will Let One Licence Cover Patient-Specific Gene Edits, and CMS Is Taking Its Medicaid Gene Therapy Deals Beyond Sickle Cell
NICE Backed Arrowhead’s Plozasiran Eight Days After UK Authorisation, as a Cost Match for 57 to 114 People in England
Canada’s Drug Agency Has Drafted a Yes on Spinraza for Adults With SMA, Four Years After Telling Provinces Not to Pay
Enhertu Won EU Approval 39 Days After Its CHMP Opinion, and Payers Now Hold a Label Wider Than the Trial
China Approved Bayer’s Asundexian, the First Factor XIa Inhibitor, on a 26% Stroke Reduction, Three Years After It Lost to Apixaban
